Revvity Announces FDA Clearance for First Automated Free Testosterone Test
Revvity, Inc. (RVTY)
Company Research
Source: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.Key features of the new test include:The only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma.Rapid results on EUROIMMUN’s ChLIA platforms with the first result available in just 48 minutes a
Read more
Impact Snapshot
Event Time:
RVTY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVTY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVTY alerts
High impacting Revvity, Inc. news events
Weekly update
A roundup of the hottest topics
RVTY
News
- Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection AssayBusiness Wire
- Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software GroupBusiness Wire
- Revvity to Present at Upcoming Investor ConferencesBusiness Wire
- Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Barclays PLC from $135.00 to $140.00. They now have an "overweight" rating on the stock.MarketBeat
- Revvity, Inc. (NYSE: RVTY) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $145.00 price target on the stock, up previously from $140.00.MarketBeat
RVTY
Earnings
- 1/31/25 - Beat
RVTY
Sec Filings
- 3/6/25 - Form N-CEN
- 2/28/25 - Form N-CSR
- 2/21/25 - Form NPORT-P
- RVTY's page on the SEC website